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Over the past 5 years there has been a significant change in
approach to the HIV/AIDS epidemic in sub-Saharan Africa.
Previously, prevention measures were particularly emphasised.
It is now acknowledged that prevention and comprehensive
care which includes the provision of antiretroviral therapy are
mutually reinforcing elements of an effective response to the
epidemic.1 This shift in thinking was further strengthened by a
recent World Health Organisation (WHO) publication2  on the
delivery of highly active antiretroviral therapy (HAART) in
resource-limited settings.  
The changing environment contributed to our decision to
develop an antiretroviral treatment programme for public
sector patients at Red Cross Children’s Hospital (RCCH) at the
beginning of 2002. The programme, which is donor funded,
builds on an established ambulatory service for HIV-infected
children and their infected parents. The principal objective is to
extend access to HAART to as many children and/or their
infected parents as possible. Secondary objectives include
evaluating the effectiveness of the antiretroviral treatment
programme, developing the clinical expertise required to treat
large numbers of children and the establishment of a parallel
research agenda. While HAART is widely used to treat
children in rich countries, there are virtually no reports from
sub-Saharan Africa on the use or effectiveness of HAART in
children treated within the public sector. In this report we
document our initial treatment experience and discuss several
challenges facing the public health sector.
Methods
This prospective, cohort study describes the initial experiences
of a public sector antiretroviral treatment programme for HIV-
infected children and their infected parents at RCCH. This
report focuses primarily on the early response of children to
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Objective. To describe the initial experience of treating HIV-
infected children and their infected parents with antiretroviral
therapy.
Design. Prospective, cohort study.
Setting. Tertiary, referral hospital.
Patients. HIV-infected children and their parents.
Methods. This report focuses on the early response of children
to highly active antiretroviral therapy (HAART). Children
were followed up at 4-weekly intervals. Monitoring included
initial and yearly viral load measurements, baseline and 6-
monthly CD4 counts and 4-weekly adherence checks.
Results. Between August 2002 and June 2003, 80 children were
enrolled in the programme, representing a follow-up period
of 23.9 patient-years. Seventy-five children had severe clinical
disease, severe immune suppression, or a combination of the
two. The response of children who had received HAART for ≥
6 months (N = 17) was assessed. There was no change in mass
z-score (p = 0.11) or length z-score (p = 0.37), but a significant
increase in CD4 percentage (p < 0.0001) during the first 6
months of therapy. Six-month viral loads were available for
12 children. There was a significant drop in viral load (p =
0.001) and 9 achieved undetectable levels by 6 months. Most
children achieved ≥ 85% adherence. By June 2002, 67 children
(84%) were relatively well, 1 had B-cell lymphoma, 7 (8.8%)
had died, 4 (5%) were lost to follow-up and 1 was withdrawn
from the programme. Of 57 children who completed 3
months of HAART, 12 were admitted a total of 17 times for
infectious complications. There were no severe drug reactions.
Three of 7 mothers on HAART received treatment through
the programme. 
Conclusion. These initial results suggest that many HIV-
infected children in the public sector will benefit from
antiretroviral therapy. However, both ambulatory and
inpatient facilities are required to manage children on
HAART comprehensively.
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HAART. The study period extended from August 2002 to the
end of June 2003. The Research Ethics Committee of the
University of Cape Town approved the study. Written consent
was obtained from the parents or caregivers before enrolment. 
Children were selected to start antiretroviral therapy
according to clinical and immunological criteria derived from
the Paediatric European Network for the  Treatment of AIDS
(PENTA) recommendations.3 Briefly, children with Centers for
Disease Control (CDC) clinical category C or immune category
3 disease and those with CDC clinical category B disease plus a
low CD4 percentage (< 20% if < 12 months old or < 15% if > 12
months old) qualified for treatment and were considered for
enrolment.4 These treatment guidelines are similar to the WHO
recommendations for HIV-infected children in resource-limited
settings.2 Several social criteria were included in the selection
process, primarily to ensure that the caregivers understood the
implications of antiretroviral therapy and made a long-term
commitment to the programme. Parents were selected for
treatment based on guidelines established by the WHO, i.e.
adults with WHO category III and IV disease and/or a CD4
count < 0.2 x 109/l were offered treatment.2
The preferred first-line therapy for HIV-infected children was
stavudine, lamivudine plus ritonavir (children < 10 kg or < 3
years old) or efavirenz (children > 10 kg or > 3 years old). The
monitoring plan included 4-weekly clinical review, initial and
yearly viral load measurements, baseline and 6-monthly CD4
counts and regular chemistry and haematology evaluations.
Several of the children were co-enrolled on parallel research
studies and have had more frequent viral load measurements
performed.
At each 4-weekly visit the unused medication of each child
was checked and the percentage of each antiretroviral
administered was determined. Mass and length z-scores were
calculated using EpiInfo 2000, version 1.0, Division of
Surveillance and Epidemiology, CDC, Atlanta, Georgia. Data
were analysed using  StatsDirect software, version 2.2.3,
Cheshire, UK and Microsoft Excel. Wilcoxon’s signed ranks test
was used to compare related samples. A p-value of < 0.05 was
regarded as statistically significant. 
Results
At the end of June 2003, 80 children had been enrolled on the
antiretroviral treatment programme, representing a total
follow-up period of 23.9 patient-years. Two of the 80 children
were siblings.Thirty-seven children (46.3%) were enrolled in
the 3-month period from April to the end of June 2003. Mean
age (95% confidence interval) at enrolment was 50.5 months
(CI 41.8 - 59.2 months). The female-to-male ratio was 31:49.
Seventy-five children had severe clinical disease (CDC clinical
category C), severe immune suppression (CDC immune
category 3) or a combination of severe clinical disease and
severe immune suppression. The remaining 5 children had
moderate clinical disease and moderate immune suppression.
These results indicate that the selection process was being
followed. Over 90% of the children were started on the
preferred first-line regimens. 
The response of children who had received HAART for 
≥ 6 months (N = 17) was assessed. There was no significant
change in mass z-score (p = 0.11) or length z-score (p = 0.37).
There was a significant increase in CD4 percentage (p < 0.0001)
and absolute CD4 count (p = 0.0013) over the first 6 months of
therapy (Fig. 1, left). Six-month viral load data were available
for 12 children co-enrolled on parallel research studies. There
was a significant drop in viral load (p = 0.001), with 9 of the 12
children achieving undetectable viral loads by 6 months (Fig. 1,
right). Of the 3 children who failed to achieve undetectable
viral loads by 6 months, 1 developed B-cell lymphoma
approximately 9 months into treatment. The other 2 children
were siblings with excellent recorded adherence patterns. They
are being investigated for viral resistance. Most children
achieved greater than 85% adherence (Fig. 2).
At the end of June, 67 (84%) of the children were relatively
well, the majority having shown improvements in their clinical
status. One child was deteriorating with a B-cell lymphoma
and 1 was withdrawn from treatment because of consistently
CD
4 
pe
rc
en
ta
ge
Baseline 6 Months
30
20
10
0
p < 0.0001
Lo
g 1
0 
vi
ra
l l
oa
d
Baseline 6 Mo
7
6
5
4
3
2
p < 0.0001
Lo
g 1
0 
vi
ra
l l
oa
d
Baseline 6 Months
7
6
5
4
3
2
p < 0.0001
Fig. 1. Changes in CD4 percentage (N = 17) and log10 viral load (N = 12)
during the first 6 months of antiretroviral therapy.
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Fig. 2. Percentage of children achieving ≥ 85% adherence at each 
4-weekly visit.
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poor adherence. Seven (8.8%) died during the study period.
Four children died within 2 weeks of commencing HAART, 1
due to Pneumocystis carinii pneumonia and 3 associated with
presumed sepsis. Three children died between 4 and 6 weeks
after starting HAART. All 3 had culture-proven bacterial
infections. 
Four (5%) of the children were lost to follow-up. All  had
been cared for by their mothers. Their ages at enrolment
ranged from 5 to 72 months and the duration of treatment
before exiting the programme ranged from 4 to 19 weeks. Their
initial CD4 percentages ranged from 4.2% to 15.8% and the
initial viral loads ranged from 2 600 to 2.4 million copies/ml.
Three of the 4 children exhibited poor adherence patterns, i.e.
adherence for most drugs below 75%. Adherence was not
documented for the fourth child. 
At the time of analysis only 57 children had completed 3
months of HAART. Twelve of these children were admitted a
total of 17 times during the initial 3 months on HAART. The
median time from start of antiretroviral therapy to first
admission was 19 days (range 11 - 65 days). Fig. 3 records the
spectrum of diagnoses during admission. Four of 9 patients
admitted with lower respiratory tract infection had a positive
blood culture for bacterial organisms. No severe adverse events
were recorded. However, 2 children experienced problems with
ritonavir. The first child developed persistent nausea and
vomiting soon after initiating therapy and the second child did
not tolerate the taste. Both were successfully managed by
substituting ritonavir with efavirenz. 
Sixty-five mothers were alive at enrolment, 11 had died and
the whereabouts of 3 was unknown. The median maternal CD4
count was 0.353 x 109/l (range 0.006 - 0.704). At the end of June,
7 mothers were receiving HAART, 3 having obtained therapy
at RCCH and 4 from other treatment programmes within the
Cape Metropolitan region.  The primary caregiver was the
mother (63 children), maternal grandmother 
(5 children), maternal great grandmother (1 child), sister 
(1 child) or aunt (5 children), and 5 children were in foster care.
The mean age ± standard deviation of the primary caregiver
was 31.6 ± 9.3 years. 
Discussion
The antiretroviral treatment programme at RCCH is currently
one of few programmes examining the practical implications of
therapy for public sector patients.  With a national
antiretroviral programme being planned, we elected to report
our early observations so as to assist other South African
institutions preparing for the national roll-out. Although the
programme at RCCH is still relatively new, the initial results
suggest that many children do benefit from treatment. Seventy-
five per cent of the children who had viral load assessments
done at 6 months had undetectable levels. These early results
are better than published reports from rich countries, which
show that only 25 - 40% of children experience viral load
suppression below the limits of detection.5 The high levels of
drug adherence are encouraging and are probably the reason
for the favourable response of many children. Adherence to
ritonavir was excellent, particularly in view of the fact that the
suspension is extremely unpalatable. These results probably
indicate that the initial education and support that the patients
received was appropriate. The key to ongoing success is to
ensure that high levels of adherence are maintained.6-8 We are
currently considering a number of strategies for improving
patient support including a regular support group, small group
discussion and more intensive support for caregivers of
children with consistently poor patterns of adherence.
The programme at RCCH started within an ambulatory
clinic setting. Some children developed serious medical events
during the early stages of therapy, particularly infectious
complications relating to ongoing immune suppression or
immune reconstitution disease.9 These problems are more
common in children with advanced clinical disease and/or
severe immune suppression. To optimise the care of these
children an inpatient consultation service was initiated. The
recent WHO publication2 makes little reference to the need for
inpatient facilities during the early phase of HAART. Our
experience suggests that this is an important consideration as
there are many children in South Africa with advanced HIV
infection who urgently require HAART to improve their
quality of life.
Enrolment accelerated during the 3 months up to the end of
June owing to the growing confidence and efficiency with
which staff members approached their clinical responsibilities.
Interestingly, there was no significant improvement in the
growth of the first group of children during the initial 6
months of HAART. However, there was a small subset of
children who showed marked increase in mass z-score. 
Of concern is that 4 children have already been lost to the
programme, despite extensive counselling and a commitment
from the caregivers that they would maintain a long-term
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Fig. 3. Reasons for hospitalisation during the first 3 months of
HAART (total number of admissions = 17). (LRTI = lower respiratory
tract infection, PML = progressive multifocal leuco-encephalopathy).
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relationship with the clinic. This problem is not unique to HIV
infection but could potentially undermine the long-term
effectiveness of antiretroviral treatment programmes in South
Africa if not adequately addressed. Suboptimal adherence
patterns, present in 3 of the 4 children, may be a risk factor
which identifies those at risk of being lost to follow-up.   
Treatment models for HIV-infected children in South Africa
will to some extent be determined by the effectiveness of
mother-to-child-transmission (MTCT) interventions. At present
an estimated 80 000 HIV-infected children are born in South
Africa annually.10 Intervention based on nevirapine can be
expected to reduce MTCT by 40 - 50%.11 Further significant
reductions are possible if triple combination prophylaxis is
offered to pregnant HIV-infected women.12 Consequently, the
paediatric HIV burden will be further reduced and the
potential for improved care for HIV-infected children
significantly increased. Particular attention should be given to
the training of doctors, nurses and pharmacists in the practical
aspects of administering antiretroviral therapy to ensure that
institutions are fully prepared to manage large numbers of
children. A particular problem identified at RCCH is that staff
members not directly linked to the programme were less
rigorous about optimising drug administration during hospital
admission. This issue should be addressed with adequate
education.
Recently, the initial lessons of a community clinic-based
antiretroviral programme for adults were published.13 In the
present study, we describe the early experience of a hospital-
based programme for children and their infected parents. Both
reports may spark debate about which treatment models
should be employed to roll out antiretroviral therapy
throughout South Africa. Our early observations suggest that
an integrated family model offers the best option for managing
HIV-infected children comprehensively. Although most of the
therapy may eventually be administered at primary care level,
inpatient facilities at secondary or tertiary care institutions
must be geared towards managing children with complications
arising from treatment. 
Donations to fund the programme were received from Syfrets
Trust Limited, Merck (Pty) Limited, Bristol-Myers Squibb
Foundation, Durbanville High School and the University of Cape
Town. The Paediatric AIDS Clinical Trials Group (PACTG)
supports a number of staff members employed on the programme.
Staff members of the Infectious Diseases Clinic and the
Immunology Laboratory at Red Cross Children's Hospital are
acknowledged for service excellence.
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